From target identification to lead selection
A transformative platform that facilitates the advancement of next-generation immunotherapies
To develop effective antibody-based therapeutic strategies for solid tumors, we must confront the challenges inherent in outdated discovery processes. Emglev represents a fusion of state-of-the-art technologies, providing a transformative platform for advancing next-generation immunotherapies tailored to solid tumor treatment.
This innovative amalgamation of techniques promises to revolutionize cancer treatment by introducing novel, highly effective approaches, uniquely positioned to tackle the complex challenges presented by solid tumor malignancies. Next generation immunotherapies will be at the forefront of this revolution.
Existing platforms
Target
Lack of validated target ;
Undruggable validated targets.
Undruggable validated targets.
sELECTION
Diversity ;
Immunological bias.
Immunological bias.
Screening
Lack of functionnal screening methods ;
In vitro and In vivo validation.
In vitro and In vivo validation.
Engineering
Risk, time and costs.
Therapeutic candidates
mAB : large molecular size CAR-T cell therapies (based on scFv) : oligomerization.
Time from selection to engineering: 6 to 12 months
Emglev platform
E-LIB
2 humanized single domain libraries ;
Fully synthetic sd-Ab ;
Target identification (GPCR…) from patient samples.
Fully synthetic sd-Ab ;
Target identification (GPCR…) from patient samples.
E-SCREEN
Functional screening ;
in vitro & in vivo validation.
in vitro & in vivo validation.
E-ENGINE
Modulable ;
Specificity.
Specificity.
E-BODY
Small size ;
Robust ;
Low off-target ;
No aggregation ;
Multi-format including CAR, bispecific and ADC-based therapies.
Robust ;
Low off-target ;
No aggregation ;
Multi-format including CAR, bispecific and ADC-based therapies.
Time to select a candidate : 2 months
EMGLEV Therapeutics
A unique proprietary platform and deep expertise combining all the advantages to provide unique targets and lead candidates
E-LIB
Unique fully synthetic sdAb libraries.
- Patented ;
- Target identification from patient samples ;
- Worldwide recognition.
E-ENGINE
All therapeutic formats
- CAR
- Bispecific
- ADC
- …
E-BODY
Lead candidate against any target.
- Low off-target.
- Robust ;
- Small size ;
E-SCREEN
20 Years of know-how
- In vitro and in vivo validation
- Functional screening
E-LIB
Unique fully synthetic sdAb libraries.
Patented ;
Target identification from patient samples ;
Worldwide recognition.
Target identification from patient samples ;
Worldwide recognition.
E-ENGINE
All therapeutic formats
CAR
Bispecific
ADC
…
Bispecific
ADC
…
Low off-target.
Robust ;
Small size ;
Lead candidate against any target.
E-BODY
In vitro and in vivo validation
Functional screening
20 Years of know-how
E-SCREEN
Publications
Previous slide
Next slide
© Copyright 2023 Emglev Therapeutics. All rights reserved